Peptidomimetics in cancer chemotherapy

A summary of the current status of the application of peptidomimetics in cancer therapeutics as an alternative to peptide drugs is provided. Only compounds that are used in therapy or at least under clinical trials are discussed, using inhibitors of farnesyltransferase, proteasome and matrix metallo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2007-09, Vol.9 (9), p.563-570
Main Authors: Avendaño, C, Menéndez, J C
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - pharmacology
Animals
Biomimetics - methods
Farnesyltranstransferase - antagonists & inhibitors
Farnesyltranstransferase - metabolism
Humans
Metalloproteases - antagonists & inhibitors
Metalloproteases - metabolism
Models, Biological
Neoplasms - drug therapy
Neoplasms - metabolism
Peptides - chemistry
Peptides - therapeutic use
Proteasome Endopeptidase Complex - metabolism
Proteasome Inhibitors
raf Kinases - antagonists & inhibitors
raf Kinases - metabolism
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A summary of the current status of the application of peptidomimetics in cancer therapeutics as an alternative to peptide drugs is provided. Only compounds that are used in therapy or at least under clinical trials are discussed, using inhibitors of farnesyltransferase, proteasome and matrix metalloproteinases as examples.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-007-0104-6